RNS Number : 8623K
Spectral MD Holdings, Ltd.
10 May 2022
 

 

Spectral MD Holdings, Ltd

("Spectral MD" or the "Company" or the Group")

 

Publication of Annual Financial Report

 

LONDON, U.K AND DALLAS, TX, U.S. Spectral MD Holdings, Ltd. (AIM: SMD), a predictive analytics company that develops proprietary AI algorithms and optical technology for faster and more accurate treatment decisions in wound care, announces that the Annual Report and Accounts are now available on the Company's website and have been posted to shareholders.

 

The Annual Report is available here: https://investors.spectralmd.com/financials/annual-interim-reports

 

 

For further information please contact:

 

Spectral MD Holdings, Ltd.

investors.spectralmd.com

Wensheng Fan, Chief Executive Officer

via Walbrook PR

Nils Windler, Chief Financial Officer


 


SP Angel Corporate Finance LLP (NOMAD and Joint Broker)

Tel: +44 (0)20 3470 0470

Stuart Gledhill/Caroline Rowe (Corporate Finance)

Vadim Alexandre/Rob Rees (Sales & Broking)

 

Stifel Nicolaus Europe Limited (Joint Broker)

Charles Hoare / Ben Maddison / Nick Harland / Will Palmer-Brown

 

 

 

Tel: +44 (0) 20 7710 7600

 


Walbrook PR Ltd (Media & Investor Relations)

Tel: +44 (0)20 7933 8780 or spectralMD@walbrookpr.com

Paul McManus / Sam Allen

Alice Woodings

Mob: +44 (0)7980 541 893 / +44 (0)7502 558 258

+44 (0)7407 804 654

 

 

About Spectral MD:                                                                                       

We are a dedicated team of forward-thinkers striving to revolutionize the management of wound care by "Seeing the Unknown" ® with our DeepView® Wound Imaging System.

www.spectralmd.com

info@spectralmd.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ACSALMTTMTJMTAT